Literature DB >> 17344283

Role of the foamy virus Pol cleavage site in viral replication.

Jacqueline Roy1, Maxine L Linial.   

Abstract

Foamy virus Pol precursor protein processing by the viral protease occurs at only one site, releasing a protease-reverse transcriptase and an integrase protein. To examine whether the cleavage of the Pol precursor protein is necessary for enzymatic activities and efficient viral replication, several mutations were generated around the cleavage site. All cleavage site mutants synthesize wild-type levels of Pol precursor protein. Mutants containing more than two amino acid substitutions around the cleavage site exhibit no detectable Pol processing. The Pol cleavage site is not required for the production of infectious particles in a single round of infection, but is important for subsequent rounds of viral infection. Mutations around the cleavage site affected the enzymatic activities of the protease and reverse transcriptase and prevented replication after two rounds of infection. Interestingly, Pol encapsidation is significantly reduced in some of the mutants.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17344283      PMCID: PMC1900213          DOI: 10.1128/JVI.00104-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Expression and maturation of human foamy virus Gag precursor polypeptides.

Authors:  M L Giron; S Colas; J Wybier; F Rozain; R Emanoil-Ravier
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

2.  Characterization of the human spuma retrovirus integrase by site-directed mutagenesis, by complementation analysis, and by swapping the zinc finger domain of HIV-1.

Authors:  A Pahl; R M Flügel
Journal:  J Biol Chem       Date:  1995-02-17       Impact factor: 5.157

3.  Nuclear localization of foamy virus Gag precursor protein.

Authors:  A W Schliephake; A Rethwilm
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

4.  Active foamy virus proteinase is essential for virus infectivity but not for formation of a Pol polyprotein.

Authors:  J Konvalinka; M Löchelt; H Zentgraf; R M Flügel; H G Kräusslich
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

5.  Construction of an infectious DNA clone of the full-length human spumaretrovirus genome and mutagenesis of the bel 1 gene.

Authors:  M Löchelt; H Zentgraf; R M Flügel
Journal:  Virology       Date:  1991-09       Impact factor: 3.616

6.  The human foamy virus pol gene is expressed as a Pro-Pol polyprotein and not as a Gag-Pol fusion protein.

Authors:  M Löchelt; R M Flügel
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

7.  Analysis of the role of the bel and bet open reading frames of human foamy virus by using a new quantitative assay.

Authors:  S F Yu; M L Linial
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

8.  Human foamy virus replication: a pathway distinct from that of retroviruses and hepadnaviruses.

Authors:  S F Yu; D N Baldwin; S R Gwynn; S Yendapalli; M L Linial
Journal:  Science       Date:  1996-03-15       Impact factor: 47.728

9.  Molecular biological characterization of the human foamy virus reverse transcriptase and ribonuclease H domains.

Authors:  D Kögel; M Aboud; R M Flügel
Journal:  Virology       Date:  1995-10-20       Impact factor: 3.616

10.  Sequences in pol are required for transfer of human foamy virus-based vectors.

Authors:  O Erlwein; P D Bieniasz; M O McClure
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more
  16 in total

1.  Foamy virus Pol protein expressed as a Gag-Pol fusion retains enzymatic activities, allowing for infectious virus production.

Authors:  Eun-Gyung Lee; Amber Sinicrope; Dana L Jackson; Shuyuarn F Yu; Maxine L Linial
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

2.  Foamy retrovirus integrase contains a Pol dimerization domain required for protease activation.

Authors:  Eun-Gyung Lee; Jacqueline Roy; Dana Jackson; Patrick Clark; Paul L Boyer; Stephen H Hughes; Maxine L Linial
Journal:  J Virol       Date:  2010-12-01       Impact factor: 5.103

3.  The C terminus of foamy retrovirus Gag contains determinants for encapsidation of Pol protein into virions.

Authors:  Eun-Gyung Lee; Maxine L Linial
Journal:  J Virol       Date:  2008-08-20       Impact factor: 5.103

4.  Mutations in the amino terminus of foamy virus Gag disrupt morphology and infectivity but do not target assembly.

Authors:  Rachel B Life; Eun-Gyung Lee; Scott W Eastman; Maxine L Linial
Journal:  J Virol       Date:  2008-04-23       Impact factor: 5.103

5.  Prototype foamy virus protease activity is essential for intraparticle reverse transcription initiation but not absolutely required for uncoating upon host cell entry.

Authors:  Sylvia Hütter; Erik Müllers; Nicole Stanke; Juliane Reh; Dirk Lindemann
Journal:  J Virol       Date:  2013-01-02       Impact factor: 5.103

6.  Expression of prototype foamy virus pol as a Gag-Pol fusion protein does not change the timing of reverse transcription.

Authors:  Dana L Jackson; Eun-Gyung Lee; Maxine L Linial
Journal:  J Virol       Date:  2012-11-07       Impact factor: 5.103

7.  Foamy virus Gag p71-p68 cleavage is required for template switch of the reverse transcriptase.

Authors:  Ralf Spannaus; Anna Schneider; Maximilian J Hartl; Birgitta M Wöhrl; Jochen Bodem
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

8.  Biophysical and enzymatic properties of the simian and prototype foamy virus reverse transcriptases.

Authors:  Maximilian J Hartl; Florian Mayr; Axel Rethwilm; Birgitta M Wöhrl
Journal:  Retrovirology       Date:  2010-01-29       Impact factor: 4.602

Review 9.  Foamy virus biology and its application for vector development.

Authors:  Dirk Lindemann; Axel Rethwilm
Journal:  Viruses       Date:  2011-05-11       Impact factor: 5.048

10.  Comparative studies on retroviral proteases: substrate specificity.

Authors:  József Tözsér
Journal:  Viruses       Date:  2010-01-14       Impact factor: 5.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.